The federal government has advised pharmaceutical companies AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics that they are in violation of a federal drug-pricing program. The program, called “340B,” was created in 1992. It requires drug makers to […]